These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 6424462)

  • 41. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.
    Wasserman RL
    Expert Rev Clin Immunol; 2014 Mar; 10(3):325-37. PubMed ID: 24527947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adequate patient's outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies.
    Milito C; Pulvirenti F; Pesce AM; Digiulio MA; Pandolfi F; Visentini M; Quinti I
    J Clin Immunol; 2014 Oct; 34(7):813-9. PubMed ID: 25047154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
    Günther G; Dreger B
    Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Use of 3d generation immunoglobulins in a surgical intensive care unit].
    Silenzi S; Mancini S
    Ann Ital Chir; 1985; 57(4):325-34. PubMed ID: 3939283
    [No Abstract]   [Full Text] [Related]  

  • 45. Treatment of AB deficiencies.
    Cunningham-Rundles C
    Vox Sang; 1986; 51 Suppl 2():63-8. PubMed ID: 3490056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.
    Berger M; Pinciaro PJ; Althaus A; Ballow M; Chouksey A; Moy J; Ochs H; Stein M
    J Clin Immunol; 2010 Mar; 30(2):321-9. PubMed ID: 19997861
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative opsonic activity of intravenous gamma globulin preparations for common bacterial pathogens.
    Hill HR; Augustine NH; Shigeoka AO
    Am J Med; 1984 Mar; 76(3A):61-6. PubMed ID: 6424458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of intravenous immune globulin in immunodeficiency diseases.
    Buckley RH; Schiff RI
    N Engl J Med; 1991 Jul; 325(2):110-7. PubMed ID: 2052044
    [No Abstract]   [Full Text] [Related]  

  • 49. [The anticomplementary activity of 2 intravenous gamma globulin preparations in children with acute lymphatic leukemia].
    Wahn V; von Kries R; Ebell W; Jürgens H; Göbel U
    Immun Infekt; 1984 Apr; 12(2):115-8. PubMed ID: 6442915
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A preparation of modified immune serum globulin (human) suitable for intravenous administration. Further characterization and comparison with pepsin-treated intravenous gamma globulin.
    Schroeder DD; Dumas ML
    Am J Med; 1984 Mar; 76(3A):33-9. PubMed ID: 6424455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increase of serum immunoglobulin level into the normal range in primary hypogammaglobulinaemia by dosage individualization of intravenous immunoglobulin.
    Leen CL; Yap PL; McClelland DB
    Vox Sang; 1986; 51(4):278-86. PubMed ID: 3798863
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
    Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
    J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of intravenous immune globulin in pregnant women with common variable hypogammaglobulinemia.
    Sorensen RU; Tomford JW; Gyves MT; Judge NE; Polmar SH
    Am J Med; 1984 Mar; 76(3A):73-7. PubMed ID: 6424460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survey of infection in patients receiving antibody replacement treatment for immune deficiency.
    Pettit SJ; Bourne H; Spickett GP
    J Clin Pathol; 2002 Aug; 55(8):577-80. PubMed ID: 12147649
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD.
    Berger M
    J Clin Immunol; 2011 Oct; 31(5):924-6. PubMed ID: 21643892
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency.
    Church JA; Leibl H; Stein MR; Melamed IR; Rubinstein A; Schneider LC; Wasserman RL; Pavlova BG; Birthistle K; Mancini M; Fritsch S; Patrone L; Moore-Perry K; Ehrlich HJ;
    J Clin Immunol; 2006 Jul; 26(4):388-95. PubMed ID: 16705486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Individual patient variations in the kinetics of intravenous immune globulin administration.
    Pirofsky B; Campbell SM; Montanaro A
    J Clin Immunol; 1982 Apr; 2(2 Suppl):7S-14S. PubMed ID: 7045157
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.
    Schiff RI; Rudd C
    J Clin Immunol; 1986 May; 6(3):256-64. PubMed ID: 2424931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antibody levels to Bordetella pertussis and Neisseria meningitidis in immunodeficient patients receiving immunoglobulin replacement therapy.
    Adam E; Church JA
    J Clin Immunol; 2015 Feb; 35(2):213-7. PubMed ID: 25631528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective evaluation of Streptococcus pneumoniae serum antibodies in patients with primary immunodeficiency on regular intravenous immunoglobulin treatment.
    Simão-Gurge RM; Costa-Carvalho BT; Nobre FA; Gonzalez IG; de Moraes-Pinto MI
    Allergol Immunopathol (Madr); 2017; 45(1):55-62. PubMed ID: 27480789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.